{"organizations": [], "uuid": "82dc28da8d6efb9b1547e479b1f773d8823569d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vertex-pharma-says-established-who/brief-vertex-pharma-says-established-wholesale-acquisition-cost-of-292000-for-symdeko-in-u-s-on-annual-basis-idUSFWN1Q21HH", "country": "US", "domain_rank": 408, "title": "BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-13T00:11:00.000+02:00", "replies_count": 0, "uuid": "82dc28da8d6efb9b1547e479b1f773d8823569d7"}, "author": "", "url": "https://www.reuters.com/article/brief-vertex-pharma-says-established-who/brief-vertex-pharma-says-established-wholesale-acquisition-cost-of-292000-for-symdeko-in-u-s-on-annual-basis-idUSFWN1Q21HH", "ord_in_thread": 0, "title": "BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "kalydeco", "sentiment": "none"}], "organizations": [{"name": "brief-vertex pharma", "sentiment": "negative"}, {"name": "brief-vertex pharma says established wholesale acquisition cost", "sentiment": "negative"}, {"name": "vertex pharma", "sentiment": "none"}, {"name": "sec", "sentiment": "none"}, {"name": "symdeko in u.s. on annual basis reuters staff", "sentiment": "none"}, {"name": "vertex pharmaceuticals inc", "sentiment": "none"}, {"name": "vertex", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "vertex pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)\n* VERTEX PHARMA SAYS ANTICIPATE FY 2018 TOTAL CF NET PRODUCT REVENUE OF $2.65 BILLION TO $2.80 BILLION FROM KALYDECO, ORKAMBI AND SYMDEKO - SEC FILING\n* VERTEX PHARMACEUTICALS -REITERATING ‍COMBINED GAAP RESEARCH AND DEVELOPMENT, SALES, GENERAL, ADMINISTRATIVE EXPENSES IN 2018 TO BE IN RANGE OF $1.80 TO $1.95 BILLION\n* VERTEX PHARMA- ‍ REITERATING COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SALES, GENERAL, AND ADMINISTRATIVE EXPENSES WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION IN 2018​ Source text: ( bit.ly/2BTkdmr ) Further company coverage:\n ", "external_links": [], "published": "2018-02-13T00:11:00.000+02:00", "crawled": "2018-02-13T00:22:41.001+02:00", "highlightTitle": ""}